- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05015868
Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies
Contribution of Genetics, Non-invasive Neurophysiological Methods, Neuroimaging and Neuropsychology in Identifying the Cause and the Epileptogenic Zone in Focal Cryptogenic Epilepsies
Patients with cryptogenic focal epilepsy (unknown cause) represent about the 30% of the entire population of epilepsy patients. Among them, about 30% are drug-resistant. The implementation of of high-field magnetic resonance imaging resolution, the new Next Generation Sequencing techniques,and innovative non-invasive neurophysiological methods (Electroencephalogram-Functional magnetic resonance imaging and High Density-Electroencephalogram) could provide a superior identification of the epileptogenic zone and therefore an increased access to epilepsy surgery.
Despite this, patients with cryptogenic epilepsy require more frequently invasive methods of presurgical study and they have more unfavorable results than patients with lesions detectable on magnetic resonance imaging. Within this context, the study is aimed at integrating the neurophysiological, radiological, neuropsychological and genetic aspects of patients with focal cryptogenic epilepsy in order to evaluate their surgical eligibility,sparing invasive methods.
Study Overview
Status
Conditions
Detailed Description
The investigators foresee study duration of 36 months and the enrollment of about 20-25 patients, affected by cryptogenic epilepsy with onset during pediatric age (0-18 years), not only to identify the cause of epilepsy and the epileptogenic zone, but also to define in a non-invasive manner, the patient's possible eligibility for surgical therapy.
Innovative neurophysiological methods, such as combined Electroencephalogram-Functional magnetic resonance imaging recording and high resolution electroencephalogram, in addition to 7 Tesla brain magnetic resonance imaging (available through the Imago7 non-profit foundation), neuropsychological studies and genetic tests through Next generation sequencing allow an advanced pre-surgical study free from the risks and discomforts caused by invasive methods. The systematic use of these diagnostic approaches will implement the knowledge and skills of the teams and it will stimulate their use in the clinical daily practise, especially for pediatric patients.
In addition to that, the investigators would like to analyse descriptive indications relating to the diagnostic sensitivity of the combined Electroencephalogram-Functional magnetic resonance imaging recording, High Density-electroencephalogram and 7 Tesla magnetic resonance imaging in the identification of the epileptogenic zone, in patients with cryptogenic focal epilepsy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stefania Zambrano, MD
- Phone Number: +039031877345
- Email: stefania.zambrano@lanostrafamiglia.it
Study Locations
-
-
Lecco
-
Bosisio Parini, Lecco, Italy, 23842
- Recruiting
- Scientific Institute IRCCS Eugenio Medea
-
Contact:
- Stefania Zambrano, MD
- Phone Number: +39031877345
- Email: stefania.zambrano@lanostrafamiglia.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- focal epilepsy, onset during pediatric age (<18 y)
- drug resistance
- unknown cause
- Brain magnetic resonance imaging negative
Exclusion Criteria:
- epilepsy with good therapeutic control
- focal symptomatic epilepsy
- age limits onset (> 18 y)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)
Step1: standard of care.
Step 2: experimental - combined Electroencephalogram-Functional brain magnetic resonance imaging registration. Step 3: experimental In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:
|
Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;
A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal. During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities. In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of the epileptogenic zone.
Time Frame: through study completion, an average of 1 year
|
Identification of the epileptogenic zone.
Identification of non-invasive methods (Electroencephalogram-Functional magnetic resonance imaging, High Density-Electroencephalogram and 7 Tesla brain magnetic resonance imaging) in order to provide the necessary and crucial data, allowing the patient access to the epilepsy surgery without recurring to invasive methods.
The calculation of the sample size was carried out on the basis of the primary objective of non-invasive identification of the epileptogenic zone.
60 patients will be sufficient to estimate the proportion of subjects treated with an effect size of 0.5, a power of 90% and a first type error of 5%.
(60 patients are obtained by including patients from Conegliano).
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic sensitivity comparison
Time Frame: through study completion, an average of 1 year
|
Diagnostic sensitivity comparison between combined Electroencephalogram-Functional magnetic resonance imaging and High Density-Electroencephalogram or 7Tesla brain magnetic resonance imaging recording for a patients subgroup.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stefania Zambrano, MD, Scientific Institute IRCCS Eugenio Medea
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 879
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsies, Partial
-
UCB PharmaCompleted
-
UCB PharmaCompletedPartial EpilepsiesUnited States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
-
UCB BIOSCIENCES, Inc.CompletedPartial Epilepsies | Partial Onset SeizuresUnited States
-
UCB BIOSCIENCES, Inc.CompletedPartial EpilepsiesUnited States
-
UCB PharmaCompletedPartial EpilepsiesUnited States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
-
Institut National de la Santé Et de la Recherche...Unknown
-
UCB BIOSCIENCES, Inc.CompletedPartial Epilepsies | Partial Onset SeizuresUnited States
-
Vertex Pharmaceuticals IncorporatedTerminatedEpilepsyUnited States, Germany
-
Bial - Portela C S.A.Completed
-
GlaxoSmithKlineCompleted
Clinical Trials on Standard of care
-
brett rasmussenCompleted
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted